Mirna Therapeutics Inc. (NASDAQ:MIRN) had its price target decreased by stock analysts at Citigroup Inc. from $4.50 to $2.00 in a report released on Thursday. The firm currently has a “neutral” rating on the stock.

Several other analysts also recently issued reports on MIRN. Zacks Investment Research raised shares of Mirna Therapeutics from a “hold” rating to a “buy” rating and set a $5.00 price objective for the company in a research report on Thursday, July 14th. Cantor Fitzgerald downgraded shares of Mirna Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday. Leerink Swann reiterated a “neutral” rating on shares of Mirna Therapeutics in a research note on Wednesday. HC Wainwright initiated coverage on Mirna Therapeutics in a research note on Monday, September 12th. They set a “buy” rating and a $6.00 target price for the company. Finally, Oppenheimer Holdings Inc. cut Mirna Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Wednesday. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Mirna Therapeutics currently has an average rating of “Hold” and an average target price of $6.96.

Shares of Mirna Therapeutics (NASDAQ:MIRN) traded up 2.200% during trading on Thursday, reaching $2.044. 22,178 shares of the company’s stock traded hands. The company’s market capitalization is $42.59 million. The company has a 50 day moving average of $3.11 and a 200-day moving average of $4.10. Mirna Therapeutics has a 1-year low of $1.82 and a 1-year high of $11.01.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/mirna-therapeutics-inc-mirn-given-new-2-00-price-target-at-citigroup-inc.html

About Mirna Therapeutics

Mirna Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a pipeline of micro ribonucleic acid (RNA)-based oncology therapeutics. The Company is developing mimics of naturally occurring microRNAs that are designed to restore the tumor suppressor activity and aid appropriate anti-tumor immune response.

5 Day Chart for NASDAQ:MIRN

Receive News & Ratings for Mirna Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.